Volition issues business review 2022

Henderson, nev , jan. 8, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has issued a business review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations. volition's major achievements in 2022 include: expanding access to the nu.q® vet cancer test on a worldwide basis achieving a ce mark for nu.q® nets launching its u.s. clinical product development and regulatory programs developing its nu.q® pipeline    scaling up its operations     read volition's business review here or watch the video below.
VNRX Ratings Summary
VNRX Quant Ranking